Japan
PURMX Therapeutics, Inc. is a biopharmaceutical startup based in Japan, specializing in the creation of nucleic acid medicine for disease treatment. Their proprietary technology aims to develop small RNA nucleic acid drugs targeting various genes, with a focus on delivering groundbreaking therapeutic effects. The company has made significant progress in this field, possessing a substantial amount of functional RNA screening data, and is actively expanding its research and development efforts.
Their flagship product, MIRX002, is a nucleic acid medicine designed for the treatment of malignant pleural mesothelioma. Having successfully completed non-clinical trials, PURMX is currently conducting investigator-initiated clinical trials at Hiroshima University Hospital with plans commencing in 2021.
As of 07 May 2024, PURMX Therapeutics secured a Series A investment from Keio Innovation Initiative, underscoring the confidence of notable investors in the potential of their innovative approach within the biopharma, biotechnology, and pharmaceutical industries.
